View ValuationThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsImago BioSciences 향후 성장Future 기준 점검 0/6Imago BioSciences은 연간 수입과 매출이 각각 14%와 77.7% 증가할 것으로 예상되고 EPS는 연간 23.5%만큼 증가할 것으로 예상됩니다.핵심 정보14.0%이익 성장률23.50%EPS 성장률Biotechs 이익 성장25.2%매출 성장률77.7%향후 자기자본이익률n/a애널리스트 커버리지Good마지막 업데이트n/a최근 향후 성장 업데이트Price Target Changed • Nov 22Price target increased to US$35.67Up from US$33.00, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of US$35.60. The company is forecast to post a net loss per share of US$1.93 next year compared to a net loss per share of US$2.70 last year.Price Target Changed • Nov 16Price target decreased to US$33.00Down from US$35.75, the current price target is an average from 5 analysts. New target price is 83% above last closing price of US$18.00. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$1.93 next year compared to a net loss per share of US$2.70 last year.Price Target Changed • Oct 28Price target decreased to US$33.00Down from US$35.75, the current price target is an average from 5 analysts. New target price is 95% above last closing price of US$16.95. Stock is down 36% over the past year. The company is forecast to post a net loss per share of US$1.82 next year compared to a net loss per share of US$2.70 last year.모든 업데이트 보기Recent updates공시 • Jan 13Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from NASDAQ Composite IndexImago BioSciences, Inc. has been removed from NASDAQ Composite Index공시 • Jan 12+ 1 more updateMerck Sharp & Dohme Corp. completed the acquisition of Imago BioSciences, Inc. (NasdaqGS:IMGO).Merck Sharp & Dohme Corp. entered into a definitive agreement to acquire Imago BioSciences, Inc. (NasdaqGS:IMGO) for $1.2 billion on November 19, 2022. Merck & Co will acquire Imago for $36 per share in cash. The Offer shall expire at one minute after 11:59 p.m., Eastern time on the date that is 20 Business Days after the commencement of the Offer. Imago will be obligated to pay a termination fee of $47.1 million to Merck in certain customary circumstances. The tender offer commenced on December 12, 2022, and will expire on January 10, 2022. The tender offer closed on January 10, 2023, in which, 31,307,028 shares of common stock of Imago were validly tendered and not withdrawn from the tender offer, representing approximately 89.2% of the total number of Imago’s outstanding shares. All shares not tendered into the offer will be cancelled and converted into the right to receive cash equal to the $36 offer price per share. After the completion of the merger, Imago will become a wholly owned subsidiary of Merck and the common stock of Imago will no longer be listed or traded on the Nasdaq Global Market. The consummation of the Offer is also conditioned on: (i) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”) and (ii) the tender of shares representing at least a majority of the total number of Imago’s outstanding shares, at least one Share more than 50% of the number of Shares then issued and outstanding being tendered other customary conditions. The Board of Directors of Imago BioSciences has unanimously (i) approved the execution, delivery and performance of the merger agreement and the consummation of the transactions contemplated by the merger agreement, including the Offer and the Merger, and (ii) agreed to recommend that the Imago stockholders accept the Offer and tender their shares of Company common stock pursuant to the Offer, subject to customary exceptions allowing for the exercise of the fiduciary duties of the Board of Directors of the Company under applicable law. The Board of Managers of Merck has approved this agreement. The transaction is expected to close in the first quarter of 2023. The transaction is expected to close on January 11, 2023, once all shares not tendered into the offer will be cancelled and converted into the right to receive cash equal to the $36. Saee Muzumdar of Gibson, Dunn & Crutcher LLP served as legal advisor to Merck. Benjamin A. Potter; Luke J. Bergstrom; Max Schleusener of Latham & Watkins LLP served as legal advisors to Imago. Morgan Stanley & Co. LLC acted as financial advisor to Merck in this transaction. Centerview Partners LLC acted as financial advisor to Imago. Innisfree M&A Inc. acted as information agent American Stock Transfer & Trust Company, LLC acted as depository to Merck Sharp & Dohme for the offer. Merck Sharp & Dohme Corp. completed the acquisition of Imago BioSciences, Inc. (NasdaqGS:IMGO) on January 11, 2023. At the effective time of the merger Shares not purchased pursuant to the Offer (other than certain excluded Shares as described in the Merger Agreement) were converted into the right to receive the Offer Price in cash.Recent Insider Transactions Derivative • Jan 09Chief Financial Officer exercised options to buy US$1.3m worth of stock.On the 3rd of January, Laura Eichorn exercised options to buy 37k shares at a strike price of around US$4.05, costing a total of US$150k. This transaction amounted to 18% of their direct individual holding at the time of the trade. Since March 2022, Laura has owned 207.74k shares directly. Company insiders have collectively sold US$34m more than they bought, via options and on-market transactions in the last 12 months.공시 • Dec 21Imago BioSciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in MyelofibrosisImago BioSciences, Inc. announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF). Ruxolitinib is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for multiple indications, including the treatment of intermediate or high-risk MF. The Phase 2 open-label study is being conducted at the Department of Medicine, Queen Mary Hospital and the University of Hong Kong and led by Harinder Gill, M.D. It will enroll approximately 20 participants diagnosed with MF who are either JAK inhibitor naïve or refractory to, relapsed or intolerant of ruxolitinib to assess the safety and efficacy of bomedemstat in combination with ruxolitinib. Treatment cycles will last for 28 days, consisting of an oral administration of both bomedemstat and ruxolitinib once daily.Recent Insider Transactions Derivative • Dec 19CEO & Director notifies of intention to sell stockHugh Rienhoff intends to sell 473k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of December. If the sale is conducted around the recent share price of US$35.80, it would amount to US$17m. For the year to December 2020, Hugh's total compensation was 8% salary and 92% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Hugh has owned 489.53k shares directly. Company insiders have collectively sold US$2.1m more than they bought, via options and on-market transactions in the last 12 months.공시 • Dec 13Imago BioSciences, Inc. Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022Imago BioSciences, Inc. presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF). The data were presented in a poster presentation session during the 64thAmerican Society of Hematology Annual Meeting and Exposition (ASH) taking place 10-13 December 2022. A Phase 2 data set with a cut-off date of 29 April 2022 was previously presented at the 30thEuropean Hematology Association Annual Meeting and congress (EHA) in June 2022. Updated Highlights (available data as of 18 October 2022): Of evaluable patients at 24 weeks: 65% (17/26) showed a decrease in Total Symptom Score (TSS). 19% (5/26) showed a = 50% decrease in TSS. 66% (33/50) showed spleen volume reductions from baseline. 28% (14/50) showed a = 20% spleen volume reduction. The majority of patients had a decrease in mutant allele frequencies (MAF) including driver mutations (e.g., JAK2) and high molecular risk (HMR) mutations (e.g., ASXL1). 90% (37/41) of transfusion-independent patients had stable (19/41) or improved (18/41) hemoglobin at Week 12. 85% (50/59) of patients had an improved (19/59) or stable (31/59) bone marrow fibrosis score post-baseline. No new mutations or transformations to acute myeloid leukemia (AML) while on treatment, even in patients with a high-risk of progression. Safety and Tolerability Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis. The most common non-hematologic adverse event (AE) related to bomedemstat was dysgeusia (altered taste), which occurred in 33% (30/90) of patients and led to discontinuation of the study in 1 patient. There were 44 patients who reported a total of 86 serious adverse events (SAEs), 16% of which were deemed drug-related by the investigator.공시 • Dec 01Iimago Biosciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid LeukemiaImago BioSciences, Inc. announced that the first participant has been dosed in an investigator-sponsored Phase 1 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with venetoclax (Venclexa®) in patients with relapsed or refractory acute myeloid leukemia (AML). Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care. The Phase 1 open-label study is being conducted at the University of Miami, led by Terrence J. Bradley, M.D. It will enroll approximately 18 adult participants diagnosed with AML who have failed at least one standard, front-line therapy and will assess the safety and efficacy of bomedemstat in combination with venetoclax (VenBom therapy). This combination regimen consists of once daily, oral administration of both bomedemstat and venetoclax. Participants will receive three cycles of the treatment, and may continue to receive treatment as long as they experience clinical benefit or until disease progression.공시 • Nov 23Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire Imago BioSciences, Inc. (NasdaqGS:IMGO) for $ billion $1.2 billion.Merck Sharp & Dohme Corp. entered into a definitive agreement to acquire Imago BioSciences, Inc. (NasdaqGS:IMGO) for $1.2 billion on November 19, 2022. Merck & Co will acquire Imago for $36.00 per share in cash. The Offer shall expire at one minute after 11:59 p.m., Eastern time on the date that is 20 Business Days after the commencement of the Offer. Imago will be obligated to pay a termination fee of $47,100,000.00 to Merck in certain customary circumstances. The consummation of the Offer is also conditioned on: (i) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”) and (ii) the tender of shares representing at least a majority of the total number of Imago’s outstanding shares, other customary conditions. The Board of Directors of Imago BioSciences has unanimously (i) approved the execution, delivery and performance of the merger agreement and the consummation of the transactions contemplated by the merger agreement, including the Offer and the Merger, and (ii) agreed to recommend that the Imago stockholders accept the Offer and tender their shares of Company common stock pursuant to the Offer, subject to customary exceptions allowing for the exercise of the fiduciary duties of the Board of Directors of the Company under applicable law. The Board of Managers of Merck has approved this agreement. The transaction is expected to close in the first quarter of 2023. Saee Muzumdar of Gibson, Dunn & Crutcher LLP served as legal advisor to Merck. Benjamin A. Potter; Luke J. Bergstrom; Max Schleusener of Latham & Watkins LLP served as legal advisors to Imago. Morgan Stanley & Co. LLC acted as financial advisor to Merck in this transaction. Centerview Partners LLC acted as financial advisor to ImagoPrice Target Changed • Nov 22Price target increased to US$35.67Up from US$33.00, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of US$35.60. The company is forecast to post a net loss per share of US$1.93 next year compared to a net loss per share of US$2.70 last year.Price Target Changed • Nov 16Price target decreased to US$33.00Down from US$35.75, the current price target is an average from 5 analysts. New target price is 83% above last closing price of US$18.00. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$1.93 next year compared to a net loss per share of US$2.70 last year.분석 기사 • Nov 08Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Price Target Changed • Oct 28Price target decreased to US$33.00Down from US$35.75, the current price target is an average from 5 analysts. New target price is 95% above last closing price of US$16.95. Stock is down 36% over the past year. The company is forecast to post a net loss per share of US$1.82 next year compared to a net loss per share of US$2.70 last year.공시 • Sep 02Imago BioSciences, Inc. Appoints Hsiangyi Chiang as Principal Accounting OfficerOn August 29, 2022, the Board of Directors of Imago BioSciences, Inc. (the Company), appointed HsiangyiChiang as the Company's principal accounting officer, effective immediately. Ms. Chiang, age 55, has served as the Company's Senior Vice President, Finance, since January 2022, prior to this Ms. Chiang held the role of Vice President, Finance, from February 2021. Prior to joining the Company, Ms. Chiang served as vice president of finance at Blade Therapeutics, Inc. from 2019, and from 2017 to 2019 as the head of finance and accounting at Medeor Therapeutics, Inc. From 2016 to 2017, Ms. Chiang served as vice president of finance, global controller at Establishment Labs Holdings, Inc., and from 2014 to 2016 as senior director and corporate controller at Principia Biopharma, Inc. Laura Eichorn, the Company's Chief Financial Officer, will no longer serve as the Company's principal accounting officer and will continue to serve as the Company's principal financial officer, effectively immediately.Recent Insider Transactions Derivative • Aug 26Chief Financial Officer notifies of intention to sell stockLaura Eichorn intends to sell 22k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of August. If the sale is conducted around the recent share price of US$18.39, it would amount to US$405k. Since March 2022, Laura has owned 207.74k shares directly. Company insiders have collectively sold US$2.1m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Aug 17Senior VP of Chemistry exercised options and sold US$204k worth of stockOn the 15th of August, Amy Tapper exercised 12k options at a strike price of around US$2.52 and sold these shares for an average price of US$19.18 per share. This trade did not impact their existing holding. Since March 2022, Amy has owned 119.05k shares directly. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.Seeking Alpha • Aug 12Imago BioSciences GAAP EPS of -$0.41 beats by $0.09Imago BioSciences press release (NASDAQ:IMGO): Q2 GAAP EPS of -$0.41 beats by $0.09. As of June 30, 2022, Imago had cash, cash equivalents and short-term investments of $190.0 million, compared to $217.4 million as of December 31, 2021. Based on current operating plans, management believes cash runway extends into 2025.분석 기사 • Jul 26Here's Why We're Not Too Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...공시 • Jun 11Imago BioSciences, Inc. Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022Imago BioSciences, Inc. presented updated positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis. The data were presented in a poster session during the 30th European Hematology Association Annual Meeting and Congress (EHA), taking place 9-12 June 2022. Previously, a Phase 2 data set with a cut-off of 31 October 2021 was presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition in December 2021. Updated Highlights (as of 29 April 2022 data cutoff): Of the evaluable patients at 24 weeks, 55% (28/51) showed a decrease in Total Symptom Score (TSS), 22% (11/51) showed a =50% decrease in TSS, 64% (32/50) showed spleen volume reductions; 52% (36/69) of patients had a decrease in mutant allele frequencies (MAFs) including driver mutations (e.g., JAK2) with the greater reduction in ASXL1, a high molecular risk (HMR) mutation; 90% (37/41) of transfusion-independent patients had stable or improved hemoglobin at Week 12; 85% (50/59) of patients had an improved (19/59) or stable (31/59) bone marrow fibrosis score post-baseline; No new mutations or transformation to acute myeloid lymphoma (AML) in patients with high risk of progression. Safety & Tolerability: Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis. The most common non-hematologic adverse event (AE) related to bomedemstat was dysgeusia (altered taste), which occurred in 36% of patients and dysgeusia led to discontinuation in 1 patient; There were 14 serious adverse events (SAEs) deemed related to bomedemstat per the Investigator. Details on the Imago EHA Presentation: Poster Presentation Title: A Phase 2 Study of IMG-7289 (Bomedemstat) in Patients With Advanced MyelofibrosisSession: 16. Myeloproliferative neoplasms – Clinical. Presenter: Harinder Gill, M.D., study investigator and presenter of the data, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pok Fu Lam, Hong KongDate & Time: June 10, 2022, at 10:30 AM ET.공시 • May 10Imago Biosciences, Inc Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung CancerImago BioSciences, Inc. announced that the first participant has been treated in an investigator-sponsored Phase 1/2 study of bomedemstat in combination with atezolizumab during the maintenance phase of treatment in people newly diagnosed with extensive stage small cell lung cancer. The study is being conducted in Seattle and led by Rafael Santana-Davila, M.D., associate professor at the University of Washington School of Medicine and Joseph Hiatt, M.D., Ph.D., of Fred Hutchinson Cancer Center (“Fred Hutch”), and in collaboration with the National Cancer Institute funded Fred Hutch Lung Specialized Project of Research Excellence. Bomedemstat is an inhibitor of lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in cell growth. Atezolizumab is an anti-PD-L1 monoclonal antibody medication approved by the U.S. Food and Drug Administration in 2021 as adjuvant treatment for non-small cell lung cancer. The Phase 1/2 open-label study will enroll approximately 34 participants diagnosed with ES-SCLC to establish the safety and tolerability of a combination treatment with bomedemstat and atezolizumab. Treatment cycles will last for 21 days, consisting of an oral administration of bomedemstat once daily and intravenous administration of atezolizumab on day 1. Participants are followed up after 30 days and every 12 weeks thereafter. In ongoing Phase 2 studies in bone marrow cancers, bomedemstat has been generally well-tolerated and has demonstrated significant symptom improvement for patients with essential thrombocythemia and advanced myelofibrosis.공시 • May 04Imago Biosciences Inc. Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential ThrombocythemiaImago BioSciences, Inc. announced that enrollment has been completed for the Phase 2 clinical study of bomedemstat for the treatment of essential thrombocythemia (ET) with 73 patients enrolled, exceeding the initial target enrollment of 60 patients. This study is designed to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of bomedemstat, an oral lysine-specific demethylase 1 (LSD1) inhibitor, in patients with ET who have failed at least one standard therapy. In December 2021, Imago presented a positive data update at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition from the Phase 2 ET clinical study. As a monotherapy in a 2nd line ET population, bomedemstat demonstrated significant and durable hematologic control and symptom improvement while maintaining hemoglobin levels. The data demonstrated that 93% of patients dosed for more than 6 weeks with bomedemstat achieved a reduced platelet count to within the normal range, a primary clinical objective. Based on the ASH data, bomedemstat continued to be generally well-tolerated and demonstrated an encouraging safety profile in ET patients. This Phase 2 multi-center, open-label study is designed to assess the safety, efficacy, pharmacokinetics and pharmacodynamics of bomedemstat, an oral inhibitor of LSD1, an enzyme, that plays a central role in the production of blood cells in the bone marrow (www.clinicaltrials.gov Identifier NCT04254978). Eligible patients aged 18 or older with ET who had failed at least one standard therapy and required treatment in order to lower their platelet count were considered eligible for participation in this study. Study objectives include: safety and tolerability, reduction of platelet count to =400 x 109/L in the absence of thromboembolic events and disease progression, durability of platelet as well as white blood cell (WBC) count reduction and reduction in mutant allele frequency (MAF). The trial is being conducted in the United States, the United Kingdom, Europe, New Zealand, and Australia. Plan to provide interim data at the June EHA meeting and results from the completed study in the second half of the year 2022.분석 기사 • Apr 12Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...Recent Insider Transactions Derivative • Feb 26COO & Interim CFO exercised options and sold US$153k worth of stockOn the 22nd of February, Laura Eichorn exercised 8k options at a strike price of around US$2.52 and sold these shares for an average price of US$21.60 per share. This trade did not impact their existing holding. Since September 2021, Laura has owned 207.74k shares directly. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Feb 04Senior VP of Chemistry exercised options and sold US$115k worth of stockOn the 1st of February, Amy Tapper exercised 7k options at a strike price of around US$2.10 and sold these shares for an average price of US$19.76 per share. This trade did not impact their existing holding. Since September 2021, Amy has owned 119.05k shares directly. Company insiders have collectively sold US$627k more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Jan 16Insider exercised options and sold US$254k worth of stockOn the 12th of January, Jennifer Peppe exercised 14k options at a strike price of around US$1.52 and sold these shares for an average price of US$19.68 per share. This trade did not impact their existing holding. Since September 2021, Jennifer has owned 148.81k shares directly. Company insiders have collectively sold US$512k more than they bought, via options and on-market transactions in the last 12 months.공시 • Dec 12Imago BioSciences, Inc. Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021Imago BioSciences, Inc. presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF). The data were presented in an oral session during the 63rdAmerican Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021. Previously, a Phase 2 data set with a cut-off date of May 17, 2021 was presented at the European Hematology Association 2021 Virtual Congress. Updated Highlights (as of November 1, 2021 cutoff): Of the evaluable patients at 24 weeks: 74% (17/23) showed a decrease in Total Symptom Score (TSS). 26% (6/23) showed a =50% decrease in TSS. 75% (30/40) showed spleen volume reductions. 81% (103/127) of mutant allele frequencies (MAFs) were either stable (45%) or reduced (36%), including driver and high molecular risk (HMR) mutations such as ASXL1. 89% (32/36) of patients who were transfusion-independent at baseline had stable or improved hemoglobin at 12 weeks. No new mutations or transformation to acute myeloid lymphoma (AML) in more than 600 days of follow-up in patients with high risk of progression. Safety & Tolerability: Bomedemstat was generally well-tolerated to date in patients with myelofibrosis. The most common non-hematologic AE related to bomedemstat was dysgeusia (altered taste), which occurred in 27 patients (30%). About Imago’s Phase 2 Advanced Myelofibrosis Program: Myelofibrosis (MF) is a progressive cancer in which the bone marrow is gradually replaced by fibrous, scar-like tissue. There is a significant unmet need for a disease-modifying therapy. The need is greatest in patients with MF whose disease is not adequately managed with current JAK inhibitors, the current standard of care. This Phase 2b multi-center, open-label study is designed to assess the safety, efficacy, pharmacodynamics, and spleen volume reduction of bomedemstat, an oral inhibitor of the lysine-specific demethylase 1 (LSD1). Eligible patients aged 18 or over with MF who are refractory or resistant to, intolerant of, are inadequately controlled by or ineligible for approved therapies were considered for the study. Exploratory assessments include symptom reduction, changes in cytokine profiles, changes in the frequency of mutant alleles and bone marrow fibrosis. The trial is being conducted in the United States, United Kingdom, European Union and Hong Kong. This ongoing 24-week study completed enrollment in May 2021 for a total of 89 patients.분석 기사 • Dec 08We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Executive Departure • Oct 05Chief Financial Officer Matthew Plunkett has left the companyDuring their tenure, earnings grew by 110% annually compared to the industry average of 4.9%. On the 28th of September, Matthew Plunkett left the company after less than a year in the role. We don't have any record of a personal shareholding under Matthew's name. Matthew is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 9.29 years.이익 및 매출 성장 예측NasdaqGS:IMGO - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202511-122-115-92512/31/2024N/A-111-90-110512/31/2023N/A-88-73-83612/31/2022N/A-65-60N/A69/30/2022N/A-62-52-52N/A6/30/2022N/A-57-53-53N/A3/31/2022N/A-52-44-44N/A12/31/2021N/A-42-40-40N/A9/30/2021N/A-33-31-31N/A6/30/2021N/A-26-24-24N/A3/31/2021N/A-21-20-20N/A12/31/2020N/A-18-17-17N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: IMGO 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: IMGO 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: IMGO 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: IMGO 은(는) 내년에 수익이 없을 것으로 예상됩니다.고성장 매출: IMGO 은(는) 내년에 수익이 없을 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: IMGO의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/01/12 14:36종가2023/01/10 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Imago BioSciences, Inc.는 6명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Michael SchmidtGuggenheim Securities, LLCMitchell KapoorH.C. Wainwright & Co.Maurice RaycroftJefferies LLC3명의 분석가 더 보기
Price Target Changed • Nov 22Price target increased to US$35.67Up from US$33.00, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of US$35.60. The company is forecast to post a net loss per share of US$1.93 next year compared to a net loss per share of US$2.70 last year.
Price Target Changed • Nov 16Price target decreased to US$33.00Down from US$35.75, the current price target is an average from 5 analysts. New target price is 83% above last closing price of US$18.00. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$1.93 next year compared to a net loss per share of US$2.70 last year.
Price Target Changed • Oct 28Price target decreased to US$33.00Down from US$35.75, the current price target is an average from 5 analysts. New target price is 95% above last closing price of US$16.95. Stock is down 36% over the past year. The company is forecast to post a net loss per share of US$1.82 next year compared to a net loss per share of US$2.70 last year.
공시 • Jan 13Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from NASDAQ Composite IndexImago BioSciences, Inc. has been removed from NASDAQ Composite Index
공시 • Jan 12+ 1 more updateMerck Sharp & Dohme Corp. completed the acquisition of Imago BioSciences, Inc. (NasdaqGS:IMGO).Merck Sharp & Dohme Corp. entered into a definitive agreement to acquire Imago BioSciences, Inc. (NasdaqGS:IMGO) for $1.2 billion on November 19, 2022. Merck & Co will acquire Imago for $36 per share in cash. The Offer shall expire at one minute after 11:59 p.m., Eastern time on the date that is 20 Business Days after the commencement of the Offer. Imago will be obligated to pay a termination fee of $47.1 million to Merck in certain customary circumstances. The tender offer commenced on December 12, 2022, and will expire on January 10, 2022. The tender offer closed on January 10, 2023, in which, 31,307,028 shares of common stock of Imago were validly tendered and not withdrawn from the tender offer, representing approximately 89.2% of the total number of Imago’s outstanding shares. All shares not tendered into the offer will be cancelled and converted into the right to receive cash equal to the $36 offer price per share. After the completion of the merger, Imago will become a wholly owned subsidiary of Merck and the common stock of Imago will no longer be listed or traded on the Nasdaq Global Market. The consummation of the Offer is also conditioned on: (i) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”) and (ii) the tender of shares representing at least a majority of the total number of Imago’s outstanding shares, at least one Share more than 50% of the number of Shares then issued and outstanding being tendered other customary conditions. The Board of Directors of Imago BioSciences has unanimously (i) approved the execution, delivery and performance of the merger agreement and the consummation of the transactions contemplated by the merger agreement, including the Offer and the Merger, and (ii) agreed to recommend that the Imago stockholders accept the Offer and tender their shares of Company common stock pursuant to the Offer, subject to customary exceptions allowing for the exercise of the fiduciary duties of the Board of Directors of the Company under applicable law. The Board of Managers of Merck has approved this agreement. The transaction is expected to close in the first quarter of 2023. The transaction is expected to close on January 11, 2023, once all shares not tendered into the offer will be cancelled and converted into the right to receive cash equal to the $36. Saee Muzumdar of Gibson, Dunn & Crutcher LLP served as legal advisor to Merck. Benjamin A. Potter; Luke J. Bergstrom; Max Schleusener of Latham & Watkins LLP served as legal advisors to Imago. Morgan Stanley & Co. LLC acted as financial advisor to Merck in this transaction. Centerview Partners LLC acted as financial advisor to Imago. Innisfree M&A Inc. acted as information agent American Stock Transfer & Trust Company, LLC acted as depository to Merck Sharp & Dohme for the offer. Merck Sharp & Dohme Corp. completed the acquisition of Imago BioSciences, Inc. (NasdaqGS:IMGO) on January 11, 2023. At the effective time of the merger Shares not purchased pursuant to the Offer (other than certain excluded Shares as described in the Merger Agreement) were converted into the right to receive the Offer Price in cash.
Recent Insider Transactions Derivative • Jan 09Chief Financial Officer exercised options to buy US$1.3m worth of stock.On the 3rd of January, Laura Eichorn exercised options to buy 37k shares at a strike price of around US$4.05, costing a total of US$150k. This transaction amounted to 18% of their direct individual holding at the time of the trade. Since March 2022, Laura has owned 207.74k shares directly. Company insiders have collectively sold US$34m more than they bought, via options and on-market transactions in the last 12 months.
공시 • Dec 21Imago BioSciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in MyelofibrosisImago BioSciences, Inc. announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF). Ruxolitinib is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for multiple indications, including the treatment of intermediate or high-risk MF. The Phase 2 open-label study is being conducted at the Department of Medicine, Queen Mary Hospital and the University of Hong Kong and led by Harinder Gill, M.D. It will enroll approximately 20 participants diagnosed with MF who are either JAK inhibitor naïve or refractory to, relapsed or intolerant of ruxolitinib to assess the safety and efficacy of bomedemstat in combination with ruxolitinib. Treatment cycles will last for 28 days, consisting of an oral administration of both bomedemstat and ruxolitinib once daily.
Recent Insider Transactions Derivative • Dec 19CEO & Director notifies of intention to sell stockHugh Rienhoff intends to sell 473k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of December. If the sale is conducted around the recent share price of US$35.80, it would amount to US$17m. For the year to December 2020, Hugh's total compensation was 8% salary and 92% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Hugh has owned 489.53k shares directly. Company insiders have collectively sold US$2.1m more than they bought, via options and on-market transactions in the last 12 months.
공시 • Dec 13Imago BioSciences, Inc. Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022Imago BioSciences, Inc. presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF). The data were presented in a poster presentation session during the 64thAmerican Society of Hematology Annual Meeting and Exposition (ASH) taking place 10-13 December 2022. A Phase 2 data set with a cut-off date of 29 April 2022 was previously presented at the 30thEuropean Hematology Association Annual Meeting and congress (EHA) in June 2022. Updated Highlights (available data as of 18 October 2022): Of evaluable patients at 24 weeks: 65% (17/26) showed a decrease in Total Symptom Score (TSS). 19% (5/26) showed a = 50% decrease in TSS. 66% (33/50) showed spleen volume reductions from baseline. 28% (14/50) showed a = 20% spleen volume reduction. The majority of patients had a decrease in mutant allele frequencies (MAF) including driver mutations (e.g., JAK2) and high molecular risk (HMR) mutations (e.g., ASXL1). 90% (37/41) of transfusion-independent patients had stable (19/41) or improved (18/41) hemoglobin at Week 12. 85% (50/59) of patients had an improved (19/59) or stable (31/59) bone marrow fibrosis score post-baseline. No new mutations or transformations to acute myeloid leukemia (AML) while on treatment, even in patients with a high-risk of progression. Safety and Tolerability Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis. The most common non-hematologic adverse event (AE) related to bomedemstat was dysgeusia (altered taste), which occurred in 33% (30/90) of patients and led to discontinuation of the study in 1 patient. There were 44 patients who reported a total of 86 serious adverse events (SAEs), 16% of which were deemed drug-related by the investigator.
공시 • Dec 01Iimago Biosciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid LeukemiaImago BioSciences, Inc. announced that the first participant has been dosed in an investigator-sponsored Phase 1 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with venetoclax (Venclexa®) in patients with relapsed or refractory acute myeloid leukemia (AML). Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care. The Phase 1 open-label study is being conducted at the University of Miami, led by Terrence J. Bradley, M.D. It will enroll approximately 18 adult participants diagnosed with AML who have failed at least one standard, front-line therapy and will assess the safety and efficacy of bomedemstat in combination with venetoclax (VenBom therapy). This combination regimen consists of once daily, oral administration of both bomedemstat and venetoclax. Participants will receive three cycles of the treatment, and may continue to receive treatment as long as they experience clinical benefit or until disease progression.
공시 • Nov 23Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire Imago BioSciences, Inc. (NasdaqGS:IMGO) for $ billion $1.2 billion.Merck Sharp & Dohme Corp. entered into a definitive agreement to acquire Imago BioSciences, Inc. (NasdaqGS:IMGO) for $1.2 billion on November 19, 2022. Merck & Co will acquire Imago for $36.00 per share in cash. The Offer shall expire at one minute after 11:59 p.m., Eastern time on the date that is 20 Business Days after the commencement of the Offer. Imago will be obligated to pay a termination fee of $47,100,000.00 to Merck in certain customary circumstances. The consummation of the Offer is also conditioned on: (i) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”) and (ii) the tender of shares representing at least a majority of the total number of Imago’s outstanding shares, other customary conditions. The Board of Directors of Imago BioSciences has unanimously (i) approved the execution, delivery and performance of the merger agreement and the consummation of the transactions contemplated by the merger agreement, including the Offer and the Merger, and (ii) agreed to recommend that the Imago stockholders accept the Offer and tender their shares of Company common stock pursuant to the Offer, subject to customary exceptions allowing for the exercise of the fiduciary duties of the Board of Directors of the Company under applicable law. The Board of Managers of Merck has approved this agreement. The transaction is expected to close in the first quarter of 2023. Saee Muzumdar of Gibson, Dunn & Crutcher LLP served as legal advisor to Merck. Benjamin A. Potter; Luke J. Bergstrom; Max Schleusener of Latham & Watkins LLP served as legal advisors to Imago. Morgan Stanley & Co. LLC acted as financial advisor to Merck in this transaction. Centerview Partners LLC acted as financial advisor to Imago
Price Target Changed • Nov 22Price target increased to US$35.67Up from US$33.00, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of US$35.60. The company is forecast to post a net loss per share of US$1.93 next year compared to a net loss per share of US$2.70 last year.
Price Target Changed • Nov 16Price target decreased to US$33.00Down from US$35.75, the current price target is an average from 5 analysts. New target price is 83% above last closing price of US$18.00. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$1.93 next year compared to a net loss per share of US$2.70 last year.
분석 기사 • Nov 08Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Price Target Changed • Oct 28Price target decreased to US$33.00Down from US$35.75, the current price target is an average from 5 analysts. New target price is 95% above last closing price of US$16.95. Stock is down 36% over the past year. The company is forecast to post a net loss per share of US$1.82 next year compared to a net loss per share of US$2.70 last year.
공시 • Sep 02Imago BioSciences, Inc. Appoints Hsiangyi Chiang as Principal Accounting OfficerOn August 29, 2022, the Board of Directors of Imago BioSciences, Inc. (the Company), appointed HsiangyiChiang as the Company's principal accounting officer, effective immediately. Ms. Chiang, age 55, has served as the Company's Senior Vice President, Finance, since January 2022, prior to this Ms. Chiang held the role of Vice President, Finance, from February 2021. Prior to joining the Company, Ms. Chiang served as vice president of finance at Blade Therapeutics, Inc. from 2019, and from 2017 to 2019 as the head of finance and accounting at Medeor Therapeutics, Inc. From 2016 to 2017, Ms. Chiang served as vice president of finance, global controller at Establishment Labs Holdings, Inc., and from 2014 to 2016 as senior director and corporate controller at Principia Biopharma, Inc. Laura Eichorn, the Company's Chief Financial Officer, will no longer serve as the Company's principal accounting officer and will continue to serve as the Company's principal financial officer, effectively immediately.
Recent Insider Transactions Derivative • Aug 26Chief Financial Officer notifies of intention to sell stockLaura Eichorn intends to sell 22k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of August. If the sale is conducted around the recent share price of US$18.39, it would amount to US$405k. Since March 2022, Laura has owned 207.74k shares directly. Company insiders have collectively sold US$2.1m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Aug 17Senior VP of Chemistry exercised options and sold US$204k worth of stockOn the 15th of August, Amy Tapper exercised 12k options at a strike price of around US$2.52 and sold these shares for an average price of US$19.18 per share. This trade did not impact their existing holding. Since March 2022, Amy has owned 119.05k shares directly. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.
Seeking Alpha • Aug 12Imago BioSciences GAAP EPS of -$0.41 beats by $0.09Imago BioSciences press release (NASDAQ:IMGO): Q2 GAAP EPS of -$0.41 beats by $0.09. As of June 30, 2022, Imago had cash, cash equivalents and short-term investments of $190.0 million, compared to $217.4 million as of December 31, 2021. Based on current operating plans, management believes cash runway extends into 2025.
분석 기사 • Jul 26Here's Why We're Not Too Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...
공시 • Jun 11Imago BioSciences, Inc. Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022Imago BioSciences, Inc. presented updated positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis. The data were presented in a poster session during the 30th European Hematology Association Annual Meeting and Congress (EHA), taking place 9-12 June 2022. Previously, a Phase 2 data set with a cut-off of 31 October 2021 was presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition in December 2021. Updated Highlights (as of 29 April 2022 data cutoff): Of the evaluable patients at 24 weeks, 55% (28/51) showed a decrease in Total Symptom Score (TSS), 22% (11/51) showed a =50% decrease in TSS, 64% (32/50) showed spleen volume reductions; 52% (36/69) of patients had a decrease in mutant allele frequencies (MAFs) including driver mutations (e.g., JAK2) with the greater reduction in ASXL1, a high molecular risk (HMR) mutation; 90% (37/41) of transfusion-independent patients had stable or improved hemoglobin at Week 12; 85% (50/59) of patients had an improved (19/59) or stable (31/59) bone marrow fibrosis score post-baseline; No new mutations or transformation to acute myeloid lymphoma (AML) in patients with high risk of progression. Safety & Tolerability: Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis. The most common non-hematologic adverse event (AE) related to bomedemstat was dysgeusia (altered taste), which occurred in 36% of patients and dysgeusia led to discontinuation in 1 patient; There were 14 serious adverse events (SAEs) deemed related to bomedemstat per the Investigator. Details on the Imago EHA Presentation: Poster Presentation Title: A Phase 2 Study of IMG-7289 (Bomedemstat) in Patients With Advanced MyelofibrosisSession: 16. Myeloproliferative neoplasms – Clinical. Presenter: Harinder Gill, M.D., study investigator and presenter of the data, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pok Fu Lam, Hong KongDate & Time: June 10, 2022, at 10:30 AM ET.
공시 • May 10Imago Biosciences, Inc Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung CancerImago BioSciences, Inc. announced that the first participant has been treated in an investigator-sponsored Phase 1/2 study of bomedemstat in combination with atezolizumab during the maintenance phase of treatment in people newly diagnosed with extensive stage small cell lung cancer. The study is being conducted in Seattle and led by Rafael Santana-Davila, M.D., associate professor at the University of Washington School of Medicine and Joseph Hiatt, M.D., Ph.D., of Fred Hutchinson Cancer Center (“Fred Hutch”), and in collaboration with the National Cancer Institute funded Fred Hutch Lung Specialized Project of Research Excellence. Bomedemstat is an inhibitor of lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in cell growth. Atezolizumab is an anti-PD-L1 monoclonal antibody medication approved by the U.S. Food and Drug Administration in 2021 as adjuvant treatment for non-small cell lung cancer. The Phase 1/2 open-label study will enroll approximately 34 participants diagnosed with ES-SCLC to establish the safety and tolerability of a combination treatment with bomedemstat and atezolizumab. Treatment cycles will last for 21 days, consisting of an oral administration of bomedemstat once daily and intravenous administration of atezolizumab on day 1. Participants are followed up after 30 days and every 12 weeks thereafter. In ongoing Phase 2 studies in bone marrow cancers, bomedemstat has been generally well-tolerated and has demonstrated significant symptom improvement for patients with essential thrombocythemia and advanced myelofibrosis.
공시 • May 04Imago Biosciences Inc. Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential ThrombocythemiaImago BioSciences, Inc. announced that enrollment has been completed for the Phase 2 clinical study of bomedemstat for the treatment of essential thrombocythemia (ET) with 73 patients enrolled, exceeding the initial target enrollment of 60 patients. This study is designed to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of bomedemstat, an oral lysine-specific demethylase 1 (LSD1) inhibitor, in patients with ET who have failed at least one standard therapy. In December 2021, Imago presented a positive data update at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition from the Phase 2 ET clinical study. As a monotherapy in a 2nd line ET population, bomedemstat demonstrated significant and durable hematologic control and symptom improvement while maintaining hemoglobin levels. The data demonstrated that 93% of patients dosed for more than 6 weeks with bomedemstat achieved a reduced platelet count to within the normal range, a primary clinical objective. Based on the ASH data, bomedemstat continued to be generally well-tolerated and demonstrated an encouraging safety profile in ET patients. This Phase 2 multi-center, open-label study is designed to assess the safety, efficacy, pharmacokinetics and pharmacodynamics of bomedemstat, an oral inhibitor of LSD1, an enzyme, that plays a central role in the production of blood cells in the bone marrow (www.clinicaltrials.gov Identifier NCT04254978). Eligible patients aged 18 or older with ET who had failed at least one standard therapy and required treatment in order to lower their platelet count were considered eligible for participation in this study. Study objectives include: safety and tolerability, reduction of platelet count to =400 x 109/L in the absence of thromboembolic events and disease progression, durability of platelet as well as white blood cell (WBC) count reduction and reduction in mutant allele frequency (MAF). The trial is being conducted in the United States, the United Kingdom, Europe, New Zealand, and Australia. Plan to provide interim data at the June EHA meeting and results from the completed study in the second half of the year 2022.
분석 기사 • Apr 12Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Recent Insider Transactions Derivative • Feb 26COO & Interim CFO exercised options and sold US$153k worth of stockOn the 22nd of February, Laura Eichorn exercised 8k options at a strike price of around US$2.52 and sold these shares for an average price of US$21.60 per share. This trade did not impact their existing holding. Since September 2021, Laura has owned 207.74k shares directly. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Feb 04Senior VP of Chemistry exercised options and sold US$115k worth of stockOn the 1st of February, Amy Tapper exercised 7k options at a strike price of around US$2.10 and sold these shares for an average price of US$19.76 per share. This trade did not impact their existing holding. Since September 2021, Amy has owned 119.05k shares directly. Company insiders have collectively sold US$627k more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Jan 16Insider exercised options and sold US$254k worth of stockOn the 12th of January, Jennifer Peppe exercised 14k options at a strike price of around US$1.52 and sold these shares for an average price of US$19.68 per share. This trade did not impact their existing holding. Since September 2021, Jennifer has owned 148.81k shares directly. Company insiders have collectively sold US$512k more than they bought, via options and on-market transactions in the last 12 months.
공시 • Dec 12Imago BioSciences, Inc. Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021Imago BioSciences, Inc. presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF). The data were presented in an oral session during the 63rdAmerican Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021. Previously, a Phase 2 data set with a cut-off date of May 17, 2021 was presented at the European Hematology Association 2021 Virtual Congress. Updated Highlights (as of November 1, 2021 cutoff): Of the evaluable patients at 24 weeks: 74% (17/23) showed a decrease in Total Symptom Score (TSS). 26% (6/23) showed a =50% decrease in TSS. 75% (30/40) showed spleen volume reductions. 81% (103/127) of mutant allele frequencies (MAFs) were either stable (45%) or reduced (36%), including driver and high molecular risk (HMR) mutations such as ASXL1. 89% (32/36) of patients who were transfusion-independent at baseline had stable or improved hemoglobin at 12 weeks. No new mutations or transformation to acute myeloid lymphoma (AML) in more than 600 days of follow-up in patients with high risk of progression. Safety & Tolerability: Bomedemstat was generally well-tolerated to date in patients with myelofibrosis. The most common non-hematologic AE related to bomedemstat was dysgeusia (altered taste), which occurred in 27 patients (30%). About Imago’s Phase 2 Advanced Myelofibrosis Program: Myelofibrosis (MF) is a progressive cancer in which the bone marrow is gradually replaced by fibrous, scar-like tissue. There is a significant unmet need for a disease-modifying therapy. The need is greatest in patients with MF whose disease is not adequately managed with current JAK inhibitors, the current standard of care. This Phase 2b multi-center, open-label study is designed to assess the safety, efficacy, pharmacodynamics, and spleen volume reduction of bomedemstat, an oral inhibitor of the lysine-specific demethylase 1 (LSD1). Eligible patients aged 18 or over with MF who are refractory or resistant to, intolerant of, are inadequately controlled by or ineligible for approved therapies were considered for the study. Exploratory assessments include symptom reduction, changes in cytokine profiles, changes in the frequency of mutant alleles and bone marrow fibrosis. The trial is being conducted in the United States, United Kingdom, European Union and Hong Kong. This ongoing 24-week study completed enrollment in May 2021 for a total of 89 patients.
분석 기사 • Dec 08We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Executive Departure • Oct 05Chief Financial Officer Matthew Plunkett has left the companyDuring their tenure, earnings grew by 110% annually compared to the industry average of 4.9%. On the 28th of September, Matthew Plunkett left the company after less than a year in the role. We don't have any record of a personal shareholding under Matthew's name. Matthew is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 9.29 years.